Skip to main content
Canna~Fangled Abstracts

N-acyl dopamine derivates as lead compound for implementation in transplantation medicine.

By December 10, 2014No Comments
2014 Dec 10. pii: S0955-470X(14)00118-9. doi: 10.1016/j.trre.2014.12.004. [Epub ahead of print]

Abstract

pm1Conjugates of fatty acids with ethanolamine, amino acids or monoamine neurotransmitters occur widely in nature giving rise to so-called endocannabinoids. Anandamide and 2-arachidonoyl glycerol are the best characterized endocannabinoids activating both cannabinoid receptors (CB1 and CB2) and transient receptor potential vanilloid type 1 (TRPV1) channels (anandamide) or activating cannabinoidreceptors only (2-arachidonoyl glycerol). TRPV1 is also activated by vanilloids, such as capsaicin, and endogenous neurolipins, e.g. N-arachidonoyl dopamine (NADA) and N-oleoyl dopamine (OLDA). Because donor dopamine treatment has shown to improve transplantation outcome in renal and heart recipients, this review will mainly focus on the biological activities of N-acyl dopamine derivates (NADD) as potential non-hemodynamic alternative for implementation in transplantation medicine. Hence the influence of NADD on transplantation relevant entities, i.e. cold inflicted injury, cytoprotection, I/R-injury, immune-modulation and inflammation will be summarized. The cytoprotective properties of endogenous endocannabinoids in this context will be briefly touched upon.
Copyright © 2014 Elsevier Inc. All rights reserved.
PMID:

 25576467
[PubMed – as supplied by publisher]

Publication Types

Publication Types

twin memes II